ArriVent BioPharma, Inc. (AVBP) vs CytomX Therapeutics, Inc. (CTMX)
A side-by-side comparison of ArriVent BioPharma, Inc. and CytomX Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$13.23HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
CTMX
CytomX Therapeutics, Inc.
$2.62HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
Total return — AVBP vs CTMX
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)CTMX +62.3% (+17.5%/yr)CTMX compounded faster over this window
AVBP CTMX
AVBP vs CTMX: by the numbers
- •AVBP is the larger company ($616M vs $569M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -435.21% net margin).
Metrics side by side
Valuation
| Metric | AVBP | CTMX |
|---|---|---|
| P/S ratio | N/A | 31.11 |
| P/B ratio | 1.68 | 1.88 |
Profitability
| Metric | AVBP | CTMX |
|---|---|---|
| Gross margin | 0.00% | 98.63% |
| Operating margin | 0.00% | -29.35% |
| Net margin | 0.00% | -435.21% |
| ROE | -44.63% | -26.37% |
| ROIC | -47.96% | -25.42% |
Growth (annualized)
| Metric | AVBP | CTMX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 2.18% |
| Total return CAGR (5Y) | N/A | -12.01% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.